Sure, here’s the information about Mesna Injection 100 mg/mL, with the “precautions” section specifically excluded as per your request.

Mesna Injection 100 mg/mL

Description

Mesna Injection 100 mg/mL is a sterile solution for injection containing Mesna (sodium 2-mercaptoethane sulfonate). It is a chemoprotective agent designed specifically to reduce the incidence of hemorrhagic cystitis (bleeding from the bladder) that can be caused by certain chemotherapy drugs, particularly ifosfamide and cyclophosphamide. Mesna works by detoxifying the urotoxic metabolites of these chemotherapeutic agents in the urinary tract.

Advantages

Effective Bladder Protection: Highly effective in preventing hemorrhagic cystitis, a painful and potentially serious side effect of ifosfamide and high-dose cyclophosphamide.
Allows for Chemotherapy Completion: Enables patients to receive necessary doses of bladder-toxic chemotherapy drugs by mitigating a key dose-limiting toxicity.
Rapid Action: Can be administered intravenously, allowing for quick distribution and protective action in the urinary tract.
Low Systemic Toxicity: Primarily acts in the urinary tract and is rapidly cleared from the body, leading to minimal systemic side effects compared to the chemotherapy agents it protects against.
Flexible Dosing: Can be given as intravenous boluses or continuous infusions, adapting to the specific chemotherapy regimen.

Uses

Mesna Injection 100 mg/mL is specifically used for:

Prevention of Hemorrhagic Cystitis: Prophylaxis against urothelial toxicity (damage to the lining of the bladder and urinary tract) induced by ifosfamide and, occasionally, by high-dose cyclophosphamide. It is co-administered with these chemotherapy agents.

Nature

Mesna is a sulfhydryl compound and a detoxifying agent for the urinary tract. It is designed to act as a “sacrificial thiol” within the bladder.

Its mechanism of action involves:

Binding to Acrolein: When ifosfamide and cyclophosphamide are metabolized in the body, they produce several metabolites, including acrolein. Acrolein is highly toxic to the urothelium (the cells lining the bladder), causing irritation and leading to hemorrhagic cystitis.
Forming Stable Compounds: Mesna is rapidly filtered by the kidneys and concentrates in the urine. In the urine, it reacts with and binds to acrolein and other urotoxic metabolites (like 4-hydroxy-ifosfamide/cyclophosphamide) through its sulfhydryl (-SH) group.
Neutralization and Excretion: This reaction forms stable, non-toxic, inactive compounds that are then safely excreted from the body in the urine. This prevents acrolein from coming into contact with and damaging the bladder lining.

Mesna does not interfere with the antitumor activity of ifosfamide or cyclophosphamide, as it only acts on their toxic metabolites in the urinary tract, not on the active chemotherapy agents themselves at their sites of action within cancer cells.

Storage

Room Temperature: Store Mesna Injection 100 mg/mL at controlled room temperature, typically between 20°C to 25°C (68°F to 77°F). Brief excursions between 15°C and 30°C (59°F and 86°F) are generally acceptable.
Protect from Light: Keep the vials in their original carton to protect them from light, which can cause degradation.
Do Not Freeze: Freezing may compromise the stability and effectiveness of the solution.
Discard Unused Portion: Mesna injection is typically provided in single-dose vials. Any unused portion should be discarded immediately after the dose is withdrawn, as it contains no preservatives.
Keep Out of Reach of Children: Store the medication in a secure place, out of sight and reach of children and pets.
Check Expiry Date: Always check the expiry date on the packaging. Do not use the injection beyond this date.